Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|February 23, 2017

PfizerCentreOne Expands Fill/Finish Services in Michigan

The company expanded fill/finish services at its facility in Kalamazoo, Michigan.

On Feb. 16, 2017, Pfizer CentreOne announced that it has expanded fill/finish services to its Kalamazoo, Michigan facility. Along with vial-filling of small molecules and biologics, the facility also provides vial-filling of sterile suspensions, expanding the company’s service portfolio. The Kalamazoo facility currently supplies drugs to more than 100 countries around the world.

Services at the Kalamazoo site now encompass small molecules and biologics, sterile suspensions, potent and controlled substances, aqueous and oil-based formulations, lyophilization, and vials 1–100mL; bulk formulation <1–1600 liters. The Kalamazoo facility also has dedicated, onsite technical, manufacturing science, regulatory affairs, and quality teams.

Source: PfizerCentreOne


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.